Takeda's zasocitinib has met its phase III endpoints in a trial for plaque psoriasis treatment. The treatment has demonstrated rapid and durable skin clearance, and Takeda is expected to seek approval for the medication. The results of the trial may position zasocitinib as a potential competitor to existing treatments, such as Sotyktu.